Eltrombopag to help collect stem cells for lymphoma treatment
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This Phase 2 study tests eltrombopag to improve collection of peripheral blood stem cells in adults with Hodgkin or non-Hodgkin lymphoma. If you’re getting a planned chemotherapy mobilization (like ESHAP, with or without an antibody), this trial may see whether eltrombopag can help your body collect the needed stem cells for transplant or further treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have Hodgkin lymphoma or non-Hodgkin lymphoma
- Your lymphoma is responding or stable after at least 2 treatment cycles (complete response, partial response, or stable disease)
- Your treatment plan includes ESHAP chemotherapy to mobilize stem-cell collection, possibly with an added antibody such as rituximab or brentuximab
- You are East Asian (as defined by the study)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests mecapegfilgrastim with chemotherapy to help your body collect enough peripheral blood stem cells for an autologous transplant (using your own cells). It’s for people with multiple myeloma or certain lymphomas who have already had some response to treatment.
This study tests a modified chemotherapy “conditioning” plan before an autologous stem cell transplant for people with non-Hodgkin lymphoma. It aims to improve how patients tolerate and recover from the transplant process.
This Phase 2 study tests eltrombopag to help people with low platelet counts caused by chemotherapy (which can increase bleeding risk). It looks at whether raising platelets can reduce bleeding problems and help you stay on track with care.
This trial compares two ways to collect your own stem cells before a transplant in people with non-Hodgkin's lymphoma who are in remission. The goal is to see which method works better for getting enough healthy cells.
This Phase 2 study tests hetrombopag to treat chemotherapy-related low platelet counts in adults with acute myeloid leukemia (AML) in remission. It aims to help keep platelets up so you can safely continue chemotherapy.
This trial tests a drug called avatrombopag (a pill) to help raise platelet counts in people who develop very low platelets after a stem cell transplant from a half-matched donor (haplo-HSCT). It aims to see if the drug is safe and effective at reducing the need for platelet transfusions.
Hear when a new Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.